Pacific Edge slashes team on US 'uncertainty'

Pacific Edge slashes team on US 'uncertainty'
(Image: PEB)
Brent Melville
Pacific Edge has halved its sales team after uncertainty over its future in its core US market, with a pending decision on whether medicare contractor Novitas will cover US testing.  The cancer diagnostic company, dual listed on the New Zealand and Australian stock exchanges, slashed its commercial team from 34 to 17 as it restructured its operations after a 17.78% drop in test volumes for its Cxbladder product in its core US market for the December quarter.The Dunedin firm said it had processed 7,172 tests during the final three months of...

More Markets

NZ sharemarket has big day: up 1.23%
Markets Market Close

NZ sharemarket has big day: up 1.23%

Big boys go bullish ... for now.

Grenon seeks to end ‘futile’ NZME board stoush
Finance

Grenon seeks to end ‘futile’ NZME board stoush

It's time for the current board to fold 'em, says coup orchestrator. 

Kathmandu recovery bright spot
Retail

Kathmandu recovery bright spot

KMD Brands declared earnings above previously stated guidance.

Jim Grenon's NZME board takes shape
Markets

Jim Grenon's NZME board takes shape

Investor's concessions to media firm could only extend to bringing CEO onto its board.